Technical Analysis for MESO - Mesoblast Limited

Grade Last Price % Change Price Change
grade F 4.72 -1.26% -0.06
MESO closed down 1.26 percent on Friday, January 18, 2019, on 67 percent of normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical MESO trend table...

Date Alert Name Type % Chg
Jan 18 50 DMA Resistance Bearish 0.00%
Jan 18 180 Bearish Setup Bearish Swing Setup 0.00%
Jan 18 Weak + Overbought Other 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 Stochastic Sell Signal Bearish -1.26%
Jan 17 Hammer Candlestick Bullish -1.26%
Jan 17 Doji - Bullish? Reversal -1.26%
Jan 17 Weak + Overbought Other -1.26%
Jan 17 Wide Bands Range Expansion -1.26%

Older signals for MESO ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative therapeutic cell-based products in Australia, the United States, and Singapore. The company is developing therapeutic products using its proprietary technology platforms, which include mesenchymal lineage adult stem cells (MLCs) to treat conditions with unmet medical needs, including cardiac diseases, spine and musculoskeletal disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. Its lead product candidates comprise MPC-150-IM for congestive heart failures; MPC-06-ID to treat chronic lower back pain due to moderate degenerative disc diseases; MSC-100-IV for the treatment of steroid refractory acute graft versus host diseases (GVHDs); and MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy. The company is also developing JR-031 for pediatric and adult GVHDs; MPC-25-IC, which is in Phase II clinical trial to treat acute cardiac ischemia; MPC-25-Osteo that has been completed Phase II clinical trial for the treatment of spinal fusion; and MPC-CBE, which is in Phase III clinical trial to treat bone marrow transplantations. The company has strategic alliances with Lonza Group for clinical and long-term commercial production of its off-the-shelf adult stem cell products; and Teva Pharmaceutical Industries Ltd. for the development and commercialization of its MPCs for cardiovascular diseases and neurologic conditions. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.
Is MESO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 8.78
52 Week Low 3.35
Average Volume 59,562
200-Day Moving Average 5.8565
50-Day Moving Average 4.7643
20-Day Moving Average 4.3705
10-Day Moving Average 4.762
Average True Range 0.2575
ADX 19.14
+DI 30.1027
-DI 24.6267
Chandelier Exit (Long, 3 ATRs ) 4.1875
Chandelier Exit (Short, 3 ATRs ) 4.1225
Upper Bollinger Band 5.3684
Lower Bollinger Band 3.3726
Percent B (%b) 0.68
BandWidth 45.665256
MACD Line 0.0577
MACD Signal Line -0.021
MACD Histogram 0.0787
Fundamentals Value
Market Cap 400.94 Million
Num Shares 84.9 Million
EPS -0.97
Price-to-Earnings (P/E) Ratio -4.87
Price-to-Sales 193.69
Price-to-Book 0.90
PEG Ratio -0.30
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.08
Resistance 3 (R3) 5.11 5.03 5.02
Resistance 2 (R2) 5.03 4.93 5.01 5.00
Resistance 1 (R1) 4.87 4.88 4.83 4.84 4.98
Pivot Point 4.79 4.79 4.77 4.77 4.79
Support 1 (S1) 4.63 4.69 4.59 4.60 4.46
Support 2 (S2) 4.55 4.64 4.53 4.44
Support 3 (S3) 4.39 4.55 4.42
Support 4 (S4) 4.36